English

HONGKONG XINCHENG GONGCHUANG TECHNOLOGY CO., LTD.

HONGKONG XINCHENG GONGCHUANG TECHNOLOGY CO., LTD.

Home > Products > SARMs Steroids > LGD -4033 Powder SARMs Steroids , fat burning Sarms For Weight Loss
 

LGD -4033 Powder SARMs Steroids , fat burning Sarms For Weight Loss

Place of Origin:
China
Brand Name:
yuancheng
Certification:
ISO9001, kosher
Model Number:

1165910-22-4

Min.Order Quantity:
10g
Price:
negotiable, favorable price for big order
Packaging Details:
diacreet package
Delivery Time:
3-7working days
Payment Terms:
Western Union, MoneyGram, T/T
Supply Ability:
500kg/month
Contact Now
 

Product Description

LGD -4033 Powder SARMs Steroids , fat burning Sarms For Weight Loss

Product Name: 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile(LGD-4033)
Synonyms: 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile(LGD-4033);LGD-4033;4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)benzonitrile;4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile
LGD-4033 CAS: 1165910-22-4
LGD-4033 MF: C14H12F6N2O
LGD-4033 MW: 338.2482992

LGD-4033 (now known as VK5211). It is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics It’s in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.

How LGD-4033 works
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.

LGD-4033 Uses


LGD is still fairly new (3-5 years), but the results have been very similar in studies and logs. LGD-4033 has undergone several recent studies and trials to find the best and safest way to use it. From these trials, the results have shown increases in lean body mass and decreases in body fat. There is also a significant increase in strength, well being, as well as healing possibilities.

effects of LGD-4033:


Bulking
LGD has shown the most ability of any SARM to put on size that could be considered a bulk. This will, of course, be dependent upon the diet used. Users that have experienced more than 10lb. increases, and have had a significant increase in calorie intake. The possibility of this type of size is present with LGD use. A recommend dosage for this type of goal would be 5-10 mg day for 8 weeks.
Cutting
LGD can be used to cut as well. It will shine more-so if ran in conjunction with SARMS S-4 and Cardarine (GW-501516). This would be similar to a SARMS triple stack that is normally ran with Ostarine, except there is a possibility of more size being put on while cutting. A good dose for this method would be 3-5 mg a day for 8 weeks.

SARMs

Name CAS NO. Usage
AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine
during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and
for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0
for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI),
increases the level of metabolic activity in skeletal muscles of mice
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11 431579-34-9 YK11: a SARM and myostatin inhibitor in one
AC262356 870888-46-3 New SARMS
SR9011 1379686-29-9 New SARMS
S23 1010396-29-8 New SARMS
GW0724 317318-84-6 New SARMS


China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

LGD -4033 Powder SARMs Steroids , fat burning Sarms For Weight Loss Images

 

Send Inquiry

*Email

Please Enter your Email Address

Subject

Inquiry About

Quick question
Please select FAQ

I'm very interested in your products; could you send me some detail reference information?

Please send me detail product specification, thank you!

May I be an agency of your products,and what's yourterms?

We intend to purchase this product, would you please send me the quotation and minimum order quantity?

*Message
I want to buy

For the best results, we recommend including the following details: -Self introduction -Required specifications -Inquire about price/MOQ